PI PepGen Inc. Stock: price and directors' dealings · United States · SEC (Form 4)Track the PepGen Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Health Care sector, PepGen Inc. has published 42 insider filings. Market capitalisation: €155.6m. The latest transaction was filed on 6 March 2026 (Cession). Among the most active insiders: McArthur James G. Every trade is accessible without an account.
€171,720
4 ops.
Sell Volume
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 6 March 2026
All Executives42 Thresholds0 Prospectus0 Other0
Declarations 42 total
▼ EVP, Head of R&D · Executives · 4 Mar 2026
1,832 shares @ US$6.23 51.8% of flow Common Stock SEC:0001835597-26-000016:0
▼ Chief Financial Officer · Executives · 4 Mar 2026
2,032 shares @ US$6.23 100.0% of flow Common Stock SEC:0001835597-26-000014:0
▼ President and CEO · Executives · 4 Mar 2026
5,144 shares @ US$6.23 18.9% of flow Common Stock SEC:0001835597-26-000012:0
◆ Chief Business & Legal Officer · Executives · 1 Mar 2026
30,717 shares 0Common Stock SEC:0001835597-26-000010:0
◆ Chief Technical Officer · Executives · 1 Mar 2026
34,557 shares 0Common Stock SEC:0001835597-26-000008:0
◆ EVP, Head of R&D · Executives · 1 Mar 2026
50,300 shares 0Common Stock SEC:0001835597-26-000006:0
◆ Chief Financial Officer · Executives · 1 Mar 2026
76,793 shares 0Common Stock SEC:0001835597-26-000004:0
◆ President and CEO · Executives · 1 Mar 2026
187,688 shares 0Common Stock SEC:0001835597-26-000002:0
◆ Chief Business & Legal Officer · Executives · 8 Dec 2025
35,000 shares 0Common Stock SEC:0001835597-25-000009:0
200,000 shares @ US$3.20 5.2% of flow Common Stock SEC:0001856079-25-000003:0
Canonical exit: 29 Dec 2025 (T+90) ▲ Director · Executives · 26 Sept 2025
9,375,000 shares @ US$3.20 50.5% of flow Common Stock SEC:0001231919-25-000265:0
Canonical exit: 25 Dec 2025 (T+90) ▲ EVP, Head of R&D · Executives · 30 May 2025
8,375 shares @ US$1.241 100.0% of flow Common Stock SEC:0001127602-25-016227:0
Canonical exit: 28 Aug 2025 (T+90) ◆ Chief Technical Officer · Executives · 20 May 2025
16,750 shares 0Common Stock SEC:0001127602-25-015213:0
▲ President and CEO · Executives · 17 Apr 2025
10,000 shares @ US$1.355 10.1% of flow Common Stock SEC:0001127602-25-012400:0
Canonical exit: 16 Jul 2025 (T+90) ▲ President and CEO · Executives · 8 Apr 2025
41,500 shares @ US$1.15 36.7% of flow Common Stock SEC:0001127602-25-011837:0
Canonical exit: 7 Jul 2025 (T+90) ◆ General Counsel · Executives · 3 Mar 2025
13,400 shares 0Common Stock SEC:0001127602-25-008369:0
◆ EVP, Head of R&D · Executives · 3 Mar 2025
19,430 shares 0Common Stock SEC:0001127602-25-008365:0
◆ President and CEO · Executives · 3 Mar 2025
60,719 shares 0Common Stock SEC:0001127602-25-008359:0
◆ Chief Financial Officer · Executives · 3 Mar 2025
23,283 shares 0Common Stock SEC:0001127602-25-008366:0
◆ Chief Financial Officer · Executives · 24 Feb 2025
3,200 shares 0Common Stock SEC:0001127602-25-006999:0
◆ General Counsel · Executives · 24 Feb 2025
3,000 shares 0Common Stock SEC:0001127602-25-007006:0
◇ Chief Medical Officer · Executives · 24 Jul 2024
201 shares @ US$10.21 0.6% of flow Common Stock SEC:0001127602-24-021044:0
◇ Chief Medical Officer · Executives · 18 Jul 2024
12,625 shares @ US$10.21 36.9% of flow Common Stock SEC:0001127602-24-020735:0
◇ Chief Medical Officer · Executives · 12 Jul 2024
3,288 shares @ US$10.21 9.6% of flow Common Stock SEC:0001127602-24-020521:0
◇ Chief Medical Officer · Executives · 1 Jul 2024
875 shares @ US$10.21 2.6% of flow Common Stock SEC:0001127602-24-019998:0
25 of 42 declarations
Load more (17 remaining) Acerca de PepGen Inc. PepGen Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias génicas para enfermedades genéticas. Cotiza en el mercado XNAS.